Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3.

ABSTRACT:

Background

Chemoresistance is a critical factor contributing to poor prognosis in clinical patients with cancer undergoing postoperative adjuvant chemotherapy. The role of gut microbiota in mediating resistance to tumour chemotherapy remains to be investigated.

Methods

Patients with CRC were categorised into clinical benefit responders (CBR) and no clinical benefit responders (NCB) based on chemotherapy efficacy. Differential bacterial analysis using 16S rRNA sequencing revealed Desulfovibrio as a distinct microbe between the two groups. Employing a syngeneic transplantation model, we assessed the effect of Desulfovibrio on chemotherapy by measuring tumour burden, weight, and Ki-67 expression. We further explored the mechanisms underlying the compromised chemotherapeutic eff

SUBMITTER: Li G 

PROVIDER: S-EPMC10950750 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature